{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:42:10Z","timestamp":1793472130234,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#am"},{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008513","name":"Thomas Jefferson University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy and safety of ganaxolone as adjunctive therapy in adults with uncontrolled partial\u2010onset seizures despite taking up to three concomitant antiepileptic drugs (\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adults aged 18\u201369\u00a0years and refractory to conventional\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s were enrolled in a multicenter, double\u2010blind, placebo\u2010controlled trial. After an 8\u2010week baseline period, patients were randomized 2:1 to ganaxolone 1,500\u00a0mg\/day or placebo for a 10\u2010week treatment period (2\u2010week forced titration and 8\u2010week maintenance) followed by either tapering or entry into an open\u2010label extension study. The primary endpoint was mean weekly seizure frequency. Secondary endpoints included the proportion of patients experiencing \u226550% reduction in seizure frequency (responder rate), percent change in mean weekly seizure frequency, seizure\u2010free days, and quality of life. Safety and tolerability assessments included adverse events (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s), treatment discontinuation, and clinical laboratory evaluations. Efficacy analyses were performed on the intent\u2010to\u2010treat population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 147 randomized patients (98 ganaxolone, 49 placebo), 131 completed the study; 95% of participants titrated up to 1,500\u00a0mg\/day and 78% maintained this dose. From baseline to endpoint, mean weekly seizure frequency decreased with ganaxolone (6.5\u20135.2) versus placebo (9.2\u201310.8), representing an 11.4% decrease versus placebo (p\u00a0=\u00a00.0489, analysis of covariance [\n                      <jats:styled-content style=\"fixed-case\">ANCOVA<\/jats:styled-content>\n                      ]). Mean percent change from baseline was \u221217.6% with ganaxolone versus 2.0% with placebo (p\u00a0=\u00a00.0144, Kruskal\u2010Wallis test). Responder rates were 24% with ganaxolone versus 15% with placebo (p\u00a0=\u00a00.19). Discontinuation due to adverse events was similar with ganaxolone (7.1%) and placebo (6.1%). Common adverse events were mild to moderate in severity and included dizziness (16.3% vs. 8.2%), fatigue (16.3% vs. 8.2%), and somnolence (13.3% vs. 2.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Ganaxolone 1,500\u00a0mg\/day reduced partial\u2010onset seizure frequency and was generally safe and well tolerated in this phase 2 study. These results support continued development of ganaxolone for adult patients with refractory partial\u2010onset seizures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/epi.13705","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T07:16:39Z","timestamp":1487834199000},"page":"558-564","source":"Crossref","is-referenced-by-count":62,"title":["Randomized, double\u2010blind, placebo\u2010controlled phase 2 study of ganaxolone as add\u2010on therapy in adults with uncontrolled partial\u2010onset seizures"],"prefix":"10.1111","volume":"58","author":[{"given":"Michael R.","family":"Sperling","sequence":"first","affiliation":[{"name":"Jefferson Comprehensive Epilepsy Center Thomas Jefferson University Philadelphia Pennsylvania U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[{"name":"Mid\u2010Atlantic Epilepsy and Sleep Center Bethesda Maryland U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tsai","sequence":"additional","affiliation":[{"name":"Marinus Pharmaceuticals Radnor Pennsylvania U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2009.01.006"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha\u2010hydroxy\u20103beta\u2010methyl\u20105alpha\u2010pregnan\u201020\u2010one), a selective, high\u2010affinity, steroid modulator of the gamma\u2010aminobutyric acid(A) receptor","volume":"280","author":"Carter RB","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3276-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.04504.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00256"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53630-3.00008-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01486.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8669-x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02870.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.08.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00170-4"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00324.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01182.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01278.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00003-7"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000217916.00225.3a"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12038"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-8914-1_12"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246254"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02529.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2014.0714"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334751.89859.7f"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.13705","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1111\/epi.13705","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T12:31:55Z","timestamp":1749990715000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/epi.13705"],"URL":"https:\/\/doi.org\/10.1111\/epi.13705","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}